Invesco’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-81,300
| Closed | -$1.76M | – | 3715 |
|
|
2017
Q2 | $1.76M | Buy |
81,300
+9,621
| +13% | +$175K | ﹤0.01% | 2658 |
|
|
2017
Q1 | $1.01M | Buy |
71,679
+9,708
| +16% | +$159K | ﹤0.01% | 3024 |
|
|
2016
Q4 | $1.16M | Sell |
61,971
-5,793
| -9% | -$98.5K | ﹤0.01% | 2914 |
|
|
2016
Q3 | $1.12M | Sell |
67,764
-58,695
| -46% | -$870K | ﹤0.01% | 2906 |
|
|
2016
Q2 | $1.7M | Sell |
126,459
-11,540
| -8% | -$168K | ﹤0.01% | 2573 |
|
|
2016
Q1 | $2.11M | Sell |
137,999
-18,989
| -12% | -$298K | ﹤0.01% | 2433 |
|
|
2015
Q4 | $3.12M | Buy |
156,988
+2,434
| +2% | +$46.3K | ﹤0.01% | 2244 |
|
|
2015
Q3 | $2.69M | Buy |
154,554
+59,653
| +63% | +$1.21M | ﹤0.01% | 2283 |
|
|
2015
Q2 | $1.92M | Buy |
94,901
+25,047
| +36% | +$483K | ﹤0.01% | 2647 |
|
|
2015
Q1 | $1.23M | Buy |
69,854
+3,846
| +6% | +$65.5K | ﹤0.01% | 2919 |
|
|
2014
Q4 | $1.07M | Sell |
66,008
-219,027
| -77% | -$4.02M | ﹤0.01% | 2932 |
|
|
2014
Q3 | $6.29M | Sell |
285,035
-58,170
| -17% | -$1.19M | ﹤0.01% | 1791 |
|
|
2014
Q2 | $6.91M | Sell |
343,205
-65,138
| -16% | -$1.1M | ﹤0.01% | 1756 |
|
|
2014
Q1 | $7.59M | Buy |
408,343
+176,069
| +76% | +$2.42M | ﹤0.01% | 1668 |
|
|
2013
Q4 | $2.34M | Sell |
232,274
-152,666
| -40% | -$1.84M | ﹤0.01% | 2570 |
|
|
2013
Q3 | $4.96M | Buy |
384,940
+139,864
| +57% | +$1.72M | ﹤0.01% | 1947 |
|
|
2013
Q2 | $2.91M | Buy |
+245,076
| New | +$2.65M | ﹤0.01% | 2154 |
|
Other funds holding AMRI
Invesco's AMRI Position: Q3 2017 in Review
Invesco sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 81,300 shares — an estimated $1.76M sold.
Invesco first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $7.59M in Q1 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Invesco reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Invesco sold 81,300 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.76M.
- Invesco first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Invesco's Albany Molecular Research Inc position peaked at $7.59M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Invesco's 13F filing for Q3 2017, filed 14 Nov 2017.